Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, has appointed Maya Martinez-Davis as an independent director to its Board of Directors. Martinez-Davis currently serves as President of GSK's U.S. Commercial business and brings extensive experience in oncology and biopharma from previous executive roles at Merck KGaA and Pfizer.
The appointment strengthens Perspective's board as the company advances its three clinical-stage programs in the radiopharmaceutical field. Martinez-Davis's expertise in commercial and clinical development in oncology aligns with the company's focus on developing alpha-emitting radioisotope treatments for various cancers.
Perspective Therapeutics (NYSE AMERICAN: CATX), una società di radiofarmaci, ha nominato Maya Martinez-Davis come amministratrice indipendente nel proprio Consiglio di Amministrazione. Martinez-Davis è attualmente President della divisione commerciale statunitense di GSK e porta con sé una vasta esperienza in oncologia e biofarmaceutica maturata in precedenti ruoli dirigenziali presso Merck KGaA e Pfizer.
La nomina rafforza il consiglio di Perspective mentre la società porta avanti i suoi tre programmi in fase clinica nel campo dei radiofarmaci. L'esperienza di Martinez-Davis nello sviluppo commerciale e clinico in oncologia è in linea con l'obiettivo dell'azienda di sviluppare terapie a base di radioisotopi emettitori alfa per diversi tipi di tumore.
Perspective Therapeutics (NYSE AMERICAN: CATX), una compañía de radiofármacos, ha designado a Maya Martinez-Davis como directora independiente de su Junta Directiva. Martinez-Davis ocupa actualmente el cargo de President de la unidad comercial en EE. UU. de GSK y aporta una amplia experiencia en oncología y biofarmacia adquirida en anteriores puestos ejecutivos en Merck KGaA y Pfizer.
El nombramiento refuerza la junta de Perspective mientras la compañía avanza con sus tres programas en fase clínica en el ámbito de los radiofármacos. La experiencia de Martinez-Davis en desarrollo comercial y clínico en oncología coincide con el enfoque de la empresa en desarrollar tratamientos con radioisótopos emisores alfa para diversos tipos de cáncer.
Perspective Therapeutics (NYSE AMERICAN: CATX)는 방사성 의약품 회사로서 이사회에 독립 이사로 Maya Martinez-Davis를 선임했습니다. Martinez-Davis는 현재 GSK의 미국 상업부문 President로 재직 중이며 Merck KGaA와 Pfizer에서의 이전 임원 경험을 통해 종양학 및 바이오제약 분야에서 풍부한 경력을 보유하고 있습니다.
이번 선임은 회사가 방사성 의약품 분야에서 세 개의 임상 단계 프로그램을 진행하는 가운데 Perspective의 이사회를 강화합니다. 종양학 분야의 상업화 및 임상 개발에 대한 Martinez-Davis의 전문성은 다양한 암에 대한 알파 방출 방사성동위원소 치료제 개발에 주력하는 회사의 방향성과 일치합니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une entreprise de radiopharmaceutiques, a nommé Maya Martinez-Davis administratrice indépendante au sein de son conseil d'administration. Martinez-Davis est actuellement President de l'activité commerciale américaine de GSK et apporte une vaste expérience en oncologie et en biopharma acquise lors de précédents postes exécutifs chez Merck KGaA et Pfizer.
Cette nomination renforce le conseil de Perspective alors que la société fait progresser ses trois programmes en phase clinique dans le domaine des radiopharmaceutiques. L'expertise de Martinez-Davis en développement commercial et clinique en oncologie correspond à l'objectif de l'entreprise de développer des traitements à base de radioisotopes émetteurs d'alpha pour divers cancers.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein Radiopharma-Unternehmen, hat Maya Martinez-Davis als unabhängiges Vorstandsmitglied in seinen Verwaltungsrat berufen. Martinez-Davis ist derzeit President des US-Commercial-Geschäfts von GSK und bringt umfassende Erfahrungen in Onkologie und Biopharma aus früheren Führungspositionen bei Merck KGaA und Pfizer mit.
Die Ernennung stärkt Perspectives Vorstand, während das Unternehmen seine drei klinischen Programme im Bereich der Radiopharmazeutika vorantreibt. Martinez-Davis’ Expertise in kommerzieller und klinischer Entwicklung in der Onkologie passt zur Ausrichtung des Unternehmens auf die Entwicklung von alfa-emittierenden Radioisotop-Therapien für verschiedene Krebsarten.
- Appointment of highly experienced executive Maya Martinez-Davis with extensive oncology and commercial expertise
- Strategic addition to support advancement of three clinical-stage programs
- Strengthened board oversight in commercial development and oncology
- None.
SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company’s Board of Directors, effective today.
Ms. Martinez-Davis currently serves as President of GSK’s U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin America at Merck KGaA, from April 2018 to August 2019, and prior to that served as Senior Vice President and Head of Global Oncology for its biopharma business from January 2016 through March 2018. Prior to joining Merck, she worked at Pfizer, Inc., from 2003 to 2015 in the areas of oncology, vaccines and specialty portfolios, including over a decade in senior executive roles. In addition, Ms. Martinez-Davis served on the Board of Directors of Mirati Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of targeted oncology therapies, from 2018 until its acquisition by Bristol Myers Squibb in January 2024. Ms. Martinez-Davis holds an undergraduate degree from Saint Louis University and a Master’s in business leadership and marketing from the IE Business Institute in Madrid, Spain.
Lori Woods, Chairperson of Perspective, commented, “The Board and I are excited to welcome Maya and look forward to working with her as we continue to guide the Company towards building long-term shareholder value. Maya brings a phenomenal breadth of experiences, which we believe are highly complementary to the experience of our existing directors and Perspective’s management team. We believe she will be a strong steward for shareholders in helping advance our clinical programs and deliver on our goal of helping cancer patients with limited treatment options.”
“I am excited to join Perspective’s Board at such a pivotal time in the rapidly evolving radiopharma field, and to help demonstrate the promise of alpha emitting radioisotopes in the treatment of cancers throughout the body,” said Ms. Martinez-Davis. “I look forward to sharing my insights and experience with the Perspective team, as the Company advances its three clinical-stage programs with potential to transform cancer treatment.”
Thijs Spoor, Perspective’s CEO, said, “I welcome the opportunity to work with Maya. Her commercial and clinical development experience in oncology will be a valuable resource for the Perspective team. We are at an exciting time in the Company’s history, as we are excited by the potential of our cutting-edge science to produce innovative new medicines that could improve patients’ lives.”
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company’s ability to build long-term shareholder value; the ability of alpha-emitting radioisotopes to treat cancers throughout the body; the Company’s ability to advance its clinical programs and develop medicines that could improve patients’ lives; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
Who is Maya Martinez-Davis and what is her role at Perspective Therapeutics (CATX)?
How many clinical-stage programs does Perspective Therapeutics (CATX) currently have?
What is Perspective Therapeutics' (CATX) main focus in cancer treatment?
What was Maya Martinez-Davis's previous board experience?
What is Maya Martinez-Davis's current position outside of Perspective Therapeutics?
